1. Revolution Medicines' Daraxonrasib Shows 'Unprecedented' Survival Data in Pancreatic Cancer Trial
A targeted pill from Revolution Medicines has delivered a potentially transformative result in metastatic pancreatic cancer, a disease with a notoriously grim prognosis. In a clinical trial, patients taking the daily pill, daraxonrasib, lived a median of 13.2 months, nearly double the 6.7-month median survival for pati...